Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.
Iskander D. et al, (2021), Sci Transl Med, 13
Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta V. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S362 - S362
CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker U. et al, (2021), ONCOLOGY RESEARCH AND TREATMENT, 44, 158 - 158
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O. et al, (2021), Br J Haematol, 194, 1010 - 1015
Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Mesa R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S360 - S360
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA. et al, (2021), Leukemia, 35, 2424 - 2430
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D. et al, (2021), Hematol Oncol Clin North Am, 35, 279 - 293
CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 96 - 96
Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 101 - 102
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C. et al, (2021), J Exp Med, 218
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
Louka E. et al, (2021), Journal of Experimental Medicine, 218
Application of Single Cell Approaches to Study MPN biology
MEAD A., (2021), Hematology / Oncology Clinics of North America
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S. et al, (2021), Future oncology (London, England)
TARGET-Seq: A Protocol for High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2020), STAR protocols, 1, 100125 - 100125
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT. et al, (2020), Blood Adv, 4, 5825 - 5835